These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83. Regulation of prothymosin alpha gene expression by estrogen in estrogen receptor-containing breast cancer cells via upstream half-palindromic estrogen response element motifs. Martini PG; Katzenellenbogen BS Endocrinology; 2001 Aug; 142(8):3493-501. PubMed ID: 11459795 [TBL] [Abstract][Full Text] [Related]
84. KAI1/CD82 is a novel target of estrogen receptor-mediated gene repression and downregulated in primary human breast cancer. Christgen M; Bruchhardt H; Ballmaier M; Krech T; Länger F; Kreipe H; Lehmann U Int J Cancer; 2008 Nov; 123(10):2239-46. PubMed ID: 18712725 [TBL] [Abstract][Full Text] [Related]
85. Molecular subtype profiling of invasive breast cancers weakly positive for estrogen receptor. Sheffield BS; Kos Z; Asleh-Aburaya K; Wang XQ; Leung S; Gao D; Won J; Chow C; Rachamadugu R; Stijleman I; Wolber R; Gilks CB; Myles N; Thomson T; Hayes MM; Bernard PS; Nielsen TO; Chia SK Breast Cancer Res Treat; 2016 Feb; 155(3):483-90. PubMed ID: 26846986 [TBL] [Abstract][Full Text] [Related]
86. Analysis of APOBEC3A/3B germline deletion polymorphism in breast, cervical and oral cancers from South India and its impact on miRNA regulation. Revathidevi S; Manikandan M; Rao AK; Vinothkumar V; Arunkumar G; Rajkumar KS; Ramani R; Rajaraman R; Ajay C; Munirajan AK Tumour Biol; 2016 Sep; 37(9):11983-11990. PubMed ID: 27155849 [TBL] [Abstract][Full Text] [Related]
87. APOBEC3B expression is promoted by lincNMR collaborating with TGF-β-Smad pathway. Ota K; Sakai S; Ohhata T; Suzuki T; Uchida C; Niida H; Kitagawa M Carcinogenesis; 2023 May; 44(1):1-14. PubMed ID: 36335471 [TBL] [Abstract][Full Text] [Related]
88. APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable. Vile RG; Melcher A; Pandha H; Harrington KJ; Pulido JS Clin Cancer Res; 2021 Jun; 27(12):3280-3290. PubMed ID: 33558423 [TBL] [Abstract][Full Text] [Related]
89. Genomic Characterization Revealed PM Fan R; Xu L; Cui B; Li D; Sun X; Qi Y; Rao J; Wang K; Wang C; Zhao K; Zhao Y; Dai J; Chen W; Shen H; Liu Y; Yu D Environ Sci Technol; 2023 May; 57(17):6854-6864. PubMed ID: 37071573 [TBL] [Abstract][Full Text] [Related]
90. APOBEC-induced mutations and their cancer effect size in head and neck squamous cell carcinoma. Cannataro VL; Gaffney SG; Sasaki T; Issaeva N; Grewal NKS; Grandis JR; Yarbrough WG; Burtness B; Anderson KS; Townsend JP Oncogene; 2019 May; 38(18):3475-3487. PubMed ID: 30647454 [TBL] [Abstract][Full Text] [Related]
91. APOBEC-Induced Cancer Mutations Are Uniquely Enriched in Early-Replicating, Gene-Dense, and Active Chromatin Regions. Kazanov MD; Roberts SA; Polak P; Stamatoyannopoulos J; Klimczak LJ; Gordenin DA; Sunyaev SR Cell Rep; 2015 Nov; 13(6):1103-1109. PubMed ID: 26527001 [TBL] [Abstract][Full Text] [Related]
92. Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women. Park C; Yoon KA; Kim J; Park IH; Park SJ; Kim MK; Jang W; Cho SY; Park B; Kong SY; Lee ES Cancer Sci; 2019 May; 110(5):1760-1770. PubMed ID: 30811755 [TBL] [Abstract][Full Text] [Related]
93. APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Shinohara M; Io K; Shindo K; Matsui M; Sakamoto T; Tada K; Kobayashi M; Kadowaki N; Takaori-Kondo A Sci Rep; 2012; 2():806. PubMed ID: 23150777 [TBL] [Abstract][Full Text] [Related]
95. Mutation Processes in 293-Based Clones Overexpressing the DNA Cytosine Deaminase APOBEC3B. Akre MK; Starrett GJ; Quist JS; Temiz NA; Carpenter MA; Tutt AN; Grigoriadis A; Harris RS PLoS One; 2016; 11(5):e0155391. PubMed ID: 27163364 [TBL] [Abstract][Full Text] [Related]
96. APOBEC-mediated mutagenesis is a favorable predictor of prognosis and immunotherapy for bladder cancer patients: evidence from pan-cancer analysis and multiple databases. Shi R; Wang X; Wu Y; Xu B; Zhao T; Trapp C; Wang X; Unger K; Zhou C; Lu S; Buchner A; Schulz GB; Cao F; Belka C; Su C; Li M; Shu Y Theranostics; 2022; 12(9):4181-4199. PubMed ID: 35673559 [No Abstract] [Full Text] [Related]
97. APOBEC3B stratifies ovarian clear cell carcinoma with distinct immunophenotype and prognosis. Long X; Lu H; Cai MC; Zang J; Zhang Z; Wu J; Liu X; Cheng L; Cheng J; Cheung LWT; Shen Z; Zhou Y; Di W; Zhuang G; Yin X Br J Cancer; 2023 Jun; 128(11):2054-2062. PubMed ID: 36997661 [TBL] [Abstract][Full Text] [Related]
98. Apolipoprotein B mRNA-Editing Catalytic Polypeptide-Like-Induced Protein Changes in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer Throughout Disease Progression. Bos MK; Smid M; Sleijfer S; Martens JWM JCO Precis Oncol; 2022 Jan; 6():e2100190. PubMed ID: 35050709 [TBL] [Abstract][Full Text] [Related]
99. A Tumor-Promoting Phorbol Ester Causes a Large Increase in APOBEC3A Expression and a Moderate Increase in APOBEC3B Expression in a Normal Human Keratinocyte Cell Line without Increasing Genomic Uracils. Siriwardena SU; Perera MLW; Senevirathne V; Stewart J; Bhagwat AS Mol Cell Biol; 2019 Jan; 39(1):. PubMed ID: 30348839 [TBL] [Abstract][Full Text] [Related]
100. Genes dysregulated to different extent or oppositely in estrogen receptor-positive and estrogen receptor-negative breast cancers. Zhou X; Shi T; Li B; Zhang Y; Shen X; Li H; Hong G; Liu C; Guo Z PLoS One; 2013; 8(7):e70017. PubMed ID: 23875016 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]